… results for the first quarter of fiscal year … Rafael Holdings, Inc. First Quarter Fiscal Year 2025 Financial … in LipoMedix Pharmaceuticals Ltd. a clinical stage pharmaceutical company, … Ended October 31,    2024     2023  Revenues $ 128     $ 68       …

BioCryst remains a "Buy" due to ORLADEYO's proven success, potential growth, and management's confidence despite significant competition and a one-dimensional revenue stream. Q3 2024 showed mixed results with a modest revenue beat and …

… frailty early in the first quarter of 2025,” Dr. … is a non-profit scientific organization comprised of … related diseases. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: … MyMD Pharmaceuticals, Inc.), a clinical stage pharmaceutical company …

After seeing its finances plummet due to a significant cyberattack suffered in May, Ascension has started to turn around its bottom line. The hospital operator kicked off fiscal year 2025 with a $197 million loss from recurring operations, marking a $1.2 …

… disclosed in Square Pharmaceuticals'; recently … patients. Square Pharmaceuticals, the country… first quarter of this fiscal year, Square Pharmaceuticals witnessed revenue decline … profit growth in the first quarter, recording Tk609 crore in profit …

The global animal stem cell therapy market size was valued at $256.0 million in 2023 & is projected to reach $440.0 million by 2033, growing at a CAGR of 5.6%. PORTLAND, OR, UNITED STATES, December 11, 2024 /⁨EINPresswire.com⁩/ -- Allied …

BioCellgraft, Inc. advances in the choosing of a strategic marketing and distribution partner for the company's highly effective regenerative oral product line. NEW YORK, NY, UNITED STATES, December 6, 2024 /⁨EINPresswire.com⁩/ -- BioCellgraft …

… to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of … vascular malformations study in the first quarter of 2025 Cash balance will … , strategy, future operations and profitability; the delay or pause of …

… generate steady, predictable recurring revenue. Our partnership with … 16% increase over revenues in the first quarter of fiscal … hearing that biotech and pharmaceutical industry companies have … but with much higher revenue and profit margin potential. William …

… client relationship in the first quarter of this year … 2026 assumes no additional revenue from potential future … thought process of revenue and profitability balancing for next … about delineating between pharma marketing and pharma education. Balaji Gandhi …